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Abstract
Cerebral dopamine neurotrophic factor (CDNF) protein has been shown to
protect the nigrostriatal dopaminergic pathway when given as intrastriatal infu-
sions in rat and mouse models of Parkinson’s disease (PD). In this study, we
assessed the neuroprotective effect of CDNF delivered with a recombinant
adeno-associated viral (AAV) serotype 2 vector in a rat 6-hydroxydopamine
(6-OHDA) model of PD. AAV2 vectors encoding CDNF, glial cell line–derived
neurotrophic factor (GDNF), or green fluorescent protein were injected into
the rat striatum. Protein expression analysis showed that our AAV2 vector effi-
ciently delivered the neurotrophic factor genes into the brain and gave rise to a
long-lasting expression of the proteins. Two weeks after AAV2 vector injection,
6-OHDA was injected into the rat striatum, creating a progressive degeneration
of the nigrostriatal dopaminergic system. Treatment with AAV2-CDNF resulted
in a marked decrease in amphetamine-induced ipsilateral rotations while it
provided only partial protection of tyrosine hydroxylase (TH)-immunoreactive
cells in the rat substantia nigra pars compacta and TH-reactive fibers in the
striatum. Results from this study provide additional evidence that CDNF can
be considered a potential treatment of Parkinson’s disease.
Introduction
Neurotrophic factors regulate plasticity, promote survival,
and protect adult neurons from toxins and injury
(reviewed by Petrova et al. 2004 and Lindholm and Saar-
ma 2010). They are therefore considered potential drug
candidates for the treatment of neurodegenerative dis-
eases, such as Parkinson’s disease (PD), where progressive
loss of midbrain dopamine (DA) neurons affects motor
performance (Dauer and Przedborski 2003).
Cerebral dopamine neurotrophic factor (CDNF) and
mesencephalic astrocyte–derived neurotrophic factor
(MANF) represent an evolutionary conserved family of
neurotrophic factors (Lindholm et al. 2007; Parkash et al.
2009; Lindholm and Saarma 2010). In a rat 6-hydroxy-
dopamine (6-OHDA) model of PD, single injections of
CDNF and MANF proteins were able to restore function
and increase survival of midbrain DA neurons (Lindholm
et al. 2007; Voutilainen et al. 2009). In the same model,
also a 2-week continuous infusion of CDNF attenuated
the degeneration of the nigrostriatal DAergic system
(Voutilainen et al. 2011). CDNF had also a significant
neuroprotective and neurorestorative effect in the mouse
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mo-
del of PD (Airavaara et al. 2012). In addition, MANF
had survival-promoting effect on DA neurons in vitro
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(Petrova et al. 2003), and intracellularly delivered MANF
was able to block Bax-induced neuronal apoptosis
(Hellman et al. 2011). The invertebrate analog Drosophila
melanogaster MANF (DmMANF) has also been proven to
be crucial for the maturation of the nervous system and
for the maintenance of DAergic neurons in D. melanogas-
ter (Palgi et al. 2009). These observations point out a
possible implication for CDNF/MANF family of neuro-
trophic factors in the treatment of PD.
Glial cell line–derived neurotrophic factor (GDNF) has
been considered the most promising neurotrophic factor,
showing positive effects in several animal models of PD
(Hoffer et al. 1994; Kearns and Gash 1995; Tomac et al.
1995a; Gash et al. 1996; Zhang et al. 1997; Kirik et al.
2004), but not in the a-synuclein model of PD (Decressac
et al. 2011). Controversial results from clinical trials with
GDNF (Gill et al. 2003; Nutt et al. 2003; Slevin et al.
2005; Lang et al. 2006) have pointed out the importance
of effective and reliable administration techniques (dis-
cussed by Sherer et al. 2006; Ramaswamy et al. 2009).
Indeed, more emphasis should be paid on the delivery
methods, as intracranial infusion has been associated with
large variability in the diffusion of the protein (Sherer
et al. 2006). Furthermore, following sustained intrapu-
tamenal delivery, neutralizing antibodies against GDNF
could be detected in some patients, probably due to leak-
age of delivery system. Gene therapy using recombinant
viral vectors may be one answer to these problems
(reviewed by Bj€orklund and Kordower 2010).
Adeno-associated virus (AAV) has a beneficial profile,
with low toxicity, and allowing long-term gene expression
(reviewed by McCown 2005). It has become the most com-
mon vector for gene transfer in clinical trials in PD patients
(Kaplitt et al. 2007; Marks et al. 2008, 2010; LeWitt et al.
2011). The delivery of the GDNF family neurotrophic fac-
tor neurturin (NRTN) using an AAV2 vector was recently
proven to be safe and well tolerated in PD patients, even
though the clinical outcome was rather modest (Marks
et al. 2008, 2010). One major concern when delivering
therapeutic agents with viral vectors is that the level of the
expression is difficult to control, and sustained expression
of the transgene could cause negative effects. This problem
could be solved in the future as more efficiently controlled
inducible vectors are being developed.
On the basis of our previous results on the neuropro-
tective and neurorestorative effects of CDNF protein in
PD rat and mouse models (Lindholm et al. 2007; Vouti-
lainen et al. 2011; Airavaara et al. 2012), we studied the
effect of CDNF gene delivery using an AAV serotype 2
vector encoding CDNF. The protein expression following
the gene transfer was analyzed using specific
enzyme-linked immunosorbent assay (ELISA) and the
neuroprotective effect of the AAV2-CDNF gene therapy
was compared with that of AAV2-GDNF (positive con-
trol) and AAV2-GFP (green fluorescent protein) and PBS
(phosphate-buffered saline) (negative controls).
Materials and Methods
Construction, purification, and
characterization of AAV2 vectors
The open reading frame of human CDNF (hCDNF) was
cloned into the BamHI/XhoI sites of pAAV-MCS (Strata-
gene, La Jolla, CA) to create pAAV-CDNF (Fig. 1A). The
pAAV-CDNF, pAAV-GDNF (Lonka-Nevalaita et al. 2010),
and pAAV-hrGFP (Stratagene) plasmids were cotransfected
with the pHelper and the pAAV-RC (Stratagene) plasmids
into AAV-293 cells by the CaCl2 method (National Virus
Vector Laboratory, University of Eastern Finland, Kuopio,
Finland) according to the manufacturer’s instructions
(Stratagene). About 48-h posttransfection, the cells were
lysed by cycles of freeze/thaw, and the extracted recombi-
nant AAV2 viruses were purified by centrifugation using a
CsCl gradient. The virus sample was dialyzed in PBS con-
taining 12.5 mmol/L MgCl2. The titer was determined by
quantitative polymerase chain reaction (PCR) (SYBR
Green technique with primers for the cytomegalovirus
(CMV) promoter) for AAV2-CDNF (1 9 1012 virus
genomes [vg]/mL), AAV2-GDNF (5.18 9 1011 vg/mL),
and AAV2-GFP (4 9 1010 vg/mL). The in vitro transduc-
tion efficiency of AAV2-CDNF was determined by applying
the virus particles to HeLa cells that were then stained by
anti-CDNF antibody to verify CDNF expression. The
expression of all recombinant proteins was driven by the
CMV promoter.
(A)
(B)
Figure 1. Schematic drawing of the pAAV2-CDNF vector (A) and
experimental design for evaluating the neuroprotective effect of
AAV2-CDNF in a 6-OHDA partial lesion model of PD in rats (B).
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Animals and surgery
Animals
Wistar male rats (Harlan, the Netherlands) were group-
housed under standard laboratory conditions in a 12 h/
12 h dark/light cycle with free access to rodent food and
fresh tap water. All animal procedures were reviewed and
approved by the National Animal Experiment Board
(ESLH-2009-05234 Ym-23) and carried out in accordance
with the European Communities Council Directive 86/
609/EEC.
AAV2 vector injection
Rats (250–300 g) were anesthetized with isoflurane (4%
induction, 2.5–3.0% maintenance) and the recombinant
AAV2 viral vectors were injected into the rat striatum in
a stereotaxic operation. To target the striatum, viral vec-
tors were given as single injections into the left hemi-
sphere, 1.0 mm anterior and 2.7 mm lateral to bregma,
and 5.0 mm below the dura (stereotaxic coordinates
according to Paxinos and Watson 1997).
For behavioral experiments and analysis of cell sur-
vival after lesioning, rats were randomly divided into six
treatment groups (n = 9–10/group) receiving three dif-
ferent doses of AAV2-CDNF (4.0 9 107, 2.0 9 108,
1.0 9 109 vg/striatum), AAV2-GDNF (1.0 9 109 vg/stria-
tum), or one of the two negative controls (AAV2-GFP
2.0 9 108 vg/striatum or PBS).
For analysis of protein expression, rats were injected
with AAV2-CDNF 4.0 9 107 (n = 4), 2.0 9 108 (n = 4),
or 1.0 9 109 vg (n = 20), or AAV2-GDNF 1.0 9 109 vg
(n = 3) into the left striatum. The right striatum was left
intact, or injected with AAV2-GFP or PBS. Injections
were done using a stereotaxic injector (Stoelting, Wood
Dale, IL) and 10-lL syringes (Hamilton, Bonaduz, Swit-
zerland). Injection volume was set to 5 lL (AAV2 viral
stocks were, if necessary, diluted with PBS) and injection
speed was 1 lL/min, leaving the needle in place for
2 min before withdrawal. Rats received tramadol 1 mg/kg
subcutaneously (s.c.) for postoperative pain and were kept
in single cages overnight.
Lesions
For all rats in the neuroprotection study, lesioning of the
midbrain DAergic system was done 2 weeks after viral vec-
tor injections using 6-OHDA (6-OHDA hydrochloride;
Sigma, St. Louis, MO) (Fig. 1B). Thirty minutes before the
6-OHDA injections, rats received desipramine 15 mg/kg
intraperitoneally (i.p.) (desipramine hydrochloride, Sigma)
to protect noradrenergic nerve terminals from the toxin.
6-OHDA was injected under isoflurane anesthesia using
stereotaxis as described above. Rat received two injections,
each 10 lg of 6-OHDA (2.5 lg/lL, 1 lL/min), into the
left striatum according to following coordinates: A/P +1.6,
M/L +2.2, and A/P 0.4, M/L +4.0, 5.0 mm below dura.
Amphetamine-induced rotational behavior
Behavioral tests were carried out 2, 4, 6, 8, and 10 weeks
after 6-OHDA injections (Fig. 1B). Rats received an i.p.
injection of 2.5 mg/kg D-amphetamine, and complete
(360°) amphetamine-induced rotations were monitored
for 120 min using Rotorat software (Med Associates, Inc.,
St. Albans, VT). Before injecting the animals with
amphetamine, rats were attached to the equipment and
spontaneous rotations were registered for 30 min. Results
are given as net ipsilateral (ipsilateral minus contralateral)
full turns. As there was no significant difference between
the two control groups (vehicle and AAV2-GFP), results
from these groups were pooled together to one control
group (Kirik et al. 2000).
Immunohistochemistry
Ten weeks post lesion (12 weeks after AAV2 injection),
rats were perfused after receiving an overdose of pento-
barbital (90 mg/kg, i.p.; Mebunat, Orion Oyj, Espoo,
Finland). Rat brains were fixed with 4% paraformalde-
hyde for 10 min by intracardial perfusion, removed, and
postfixed for an additional 4 h floating in paraformalde-
hyde. After storage in sucrose, the brains were frozen and
cut on a sliding microtome into 40-lm-thick sections in
series of six.
Immunohistochemical staining was done on free-
floating brain sections as described previously (Voutilai-
nen et al. 2011). Primary antibodies used were mouse
monoclonal anti-tyrosine hydroxylase (anti-TH, 1:2000,
#MAB318; Millipore, Temecula, CA), rabbit polyclonal
anti-CDNF (1:10 000, #4343; ProSci, Inc., Poway, CA),
goat polyclonal anti-GDNF (1:3000, #AF-212-NA; R&D
Systems, Minneapolis, MN), and secondary antibodies
biotinylated horse-anti-mouse, goat-anti-rabbit, and
horse-anti-goat (1:200; Vector labs, Burlingame, CA),
respectively. Staining was reinforced using avidin–biotin–
enzyme complex (ABC-kit; Vector labs) and visualized
using diaminobenzidine (DAB) as a chromogen.
For colocalization studies, double immunofluorescence
labeling was applied. After labeling of CDNF, brain sec-
tions were incubated in fluorescein-conjugated goat anti-
rabbit (1:500; Thermo Scientific, Pierce Biotechnology,
Rockford, IL) for 2 h in room temperature. The brain
sections were blocked in 10% normal rabbit serum, and
labeled with mouse monoclonal anti-NeuN (1:1000,
#MAB377; Millipore, Temecula, CA, +4°C) or mouse
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monoclonal anti-TH (1:1000; Millipore, room tempera-
ture) overnight. Texas Red-conjugated rabbit anti-mouse
(1:1000; Thermo Scientific, Pierce Biotechnology) was
used as secondary antibody and was applied on the sec-
tions for 2 h in room temperature.
For imaging and morphometric analyses, all neuroana-
tomical areas were identified according to the nomencla-
ture of the rat brain atlas of Paxinos and Watson (1997).
Immunohistochemistry photomicrographs (representative
pictures) were achieved with Optronics digital camera
(Goleta, CA) connected to a microscope (Olympus BX51;
Olympus Optical, Tokyo, Japan). If necessary, the digital
pictures were corrected for brightness and contrast with
Adobe Photoshop CS5.1 software (Version 12.1; Adobe
Systems Incorporated, Mountain View, CA). The effect
on sprouting of TH-immunoreactive fibers was studied
following both gene therapy and long-term protein infu-
sion of the neurotrophic factors. Behavioral and morpho-
metric data from the protein infusion study have already
been published (Voutilainen et al. 2011). Lesions were
done in the same way as in this study, and CDNF or
GDNF proteins were infused into the lesioned striatum
for 2 weeks, starting 2 weeks post lesion. Brains were
fixed and immunohistochemically stained for TH 14
weeks post lesion (Voutilainen et al. 2011).
Morphometric analysis
For assessment of TH-reactive cells in the substantia nigra
pars compacta (SNpc) and TH-reactive fibers in the stria-
tum, the immunohistochemically stained brain sections
were blinded to the researcher.
Optical density in the striatum
For measurement of optical density of TH-reactive fibers
in the striatum, pictures of the immunohistochemically
TH-stained striatal sections were acquired with a digital
camera (Nikon Corporation, Tokyo, Japan) attached to a
stereomicroscope. TH-reactive fiber density in the striatum
was assessed by measuring the density along a line drawn
across the dorsal part of the striatum using Image-Pro Plus
software (Media Cybernetics, Bethesda, MD). All density
values were corrected for the background density. Three
coronal sections from the striatum of each rat brain were
analyzed, and the results are given as percentage of the
lesioned striatum as compared with the intact striatum.
Stereologic assessment of TH-reactive cells in SN
The number of TH-reactive cells in SNpc was estimated
according to the optical fractionator method combined
with the dissector principle with unbiased counting rules
using the Stereo Investigator platform (MicroBrightField,
Williston, VT) (Lindholm et al. 2007; Voutilainen et al.
2009). Cells in SNpc were counted bilaterally in six sec-
tions (40-lm sections, every sixth section) from each
brain ranging from approximately 4.5 to 6.0 mm poster-
ior to bregma (Paxinos and Watson 1997). Results are
given as percentage of cells in the lesioned rat SNpc as
compared with the intact SNpc.
As there were no differences between the negative con-
trol groups (vehicle and AAV2-GFP) in either the amount
of TH-reactive cells in the SNpc or TH-reactive fiber den-
sity in the striatum, the results from these groups were
pooled together to one control group.
Biochemical analysis of protein expression
Viral transduction of cells and preparation
of tissue samples
To analyze the time-dependent protein expression follow-
ing gene transfer with AAV2 vector, rats were injected
with AAV2-CDNF 1.0 9 109 vg in the left striatum, leav-
ing the right striatum intact, and decapitated 1, 2, 4, 8, or
12 weeks after injection (n = 4/time point). Another
group of animals was used for assessing the virus vector
titer-dependent protein expression. These animals
received an injection of AAV2-CDNF 4.0 9 107,
2.0 9 108, or 1.0 9 109 vg into their left striatum, while
the right striatum was used as a control (intact, or
injected with AAV2-GFP or with PBS). All rats used for
the titer-dependent expression analysis were decapitated
4 weeks after AAV2 vector injection. In a pilot study,
GDNF expression following AAV2-GDNF injection was
determined 9 weeks after viral vector injection (n = 3).
After decapitation, the brains were removed and the
SN (2-mm punch from 1-mm section) and the striatum
(in total) were collected and frozen. Samples were
homogenized in 150 lL of lysis buffer (137 mmol/L
NaCl, 20 mmol/L Tris, pH 8.2, 1% NP40, 10% glycerol,
1 mmol/L phenylmethanesulfonylfluoride, 0.5 mmol/L
NaVO3, and Complete Mini protease inhibitor cocktail
[Roche, Mannheim, Germany]) using a sonicator (Rinco
Ultrasonics, Romanshorn, Switzerland). The tissue sam-
ples were centrifuged at 15,300g for 20 min (4°C),
1 mol/L HCl was added to the supernatant (pH <2), and
the samples were incubated 30 min on ice. The pH of the
samples was neutralized (pH 7.6) using 1 mol/L NaOH,
and the samples were stored in 80°C until analysis.
CDNF-ELISA
Total CDNF concentration in the rat brain samples
was analyzed with an in-house-built double-antibody
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sandwich ELISA specific for hCDNF using standard proce-
dures. A detailed protocol for the CDNF-ELISA will be
published elsewhere (E. Galli, M. Ustav, P. Taba, A. Urtti,
M. Yliperttula, P. Pulkkila, and M. Saarma, unpubl. ms.).
Briefly, for antigen capture, a 96-well microtiter plate was
coated with antibodies against CDNF. To reduce unspe-
cific binding, the antibody-coated wells were incubated
with 3% bovine serum albumin (BSA) in PBS. After wash-
ing, homogenized brain tissue samples (or recombinant
hCDNF at eight different concentrations ranging from
0–1000 pg/mL for a standard curve) were applied on the
wells and incubated overnight at +4°C. The homogenized
SN samples were diluted 1:4 and analyzed as duplicate. In
the case of striatal samples, the control-side samples were
diluted 1:4 and analyzed as triplicate, whereas the left-side
AAV2-CDNF-injected samples were diluted 1:20, or in the
case of lower vector titers (4.0 9 107 and 2.0 9 108 vg),
samples were diluted 1:4, and analyzed as triplicate. On
the following day, the plate was washed and a detection
antibody against CDNF was added to the wells and incu-
bated 3 h at 37°C. The detection antibody was produced
in a different animal species from the coating antibody
used. Finally, the formed antibody-CDNF-antibody “sand-
wich” complexes in the wells were visualized with a horse-
radish peroxidase (HRP)-conjugated secondary antibody
and 3,3′,5,5′-tetramethylbenzidine (TMB) substrate
according to the manufacturer’s instructions (DuoSet-
ELISA Development System, R&D Systems). The concen-
tration of hCDNF (pg/mL) measured by ELISA was
compared with the total protein concentration (mg/mL)
of each brain sample determined by modified Lowry
method, with bovine gamma globulin as the standard (DC
Protein Assay, Bio-Rad Laboratories, Hercules, CA).
Sensitivity of the CDNF-ELISA to human recombinant
CDNF (Icosagen, Tartu, Estonia) was determined by calcu-
lating the mean response of ten blank samples and evaluat-
ing the mean plus three standard deviations on the
standard curve. Specificity of the ELISA was tested by mea-
suring cross-reactivity to recombinant mouse CDNF (R&D
Systems) and to human recombinant MANF (Icosagen).
GDNF-ELISA
The amount of GDNF protein in the brain samples was
analyzed using the GDNF Emax
 ImmunoAssay System
(Promega, Madison, WI) according to the instructions
from the supplier. The concentration of GDNF was
compared with the total amount of protein in the sample.
Statistical analysis
All results are given as mean values with error bars show-
ing the standard error of the mean (SEM). Statistical
analyses were performed using PASW Statistics 18 (SPSS,
Inc., Chicago, IL). For normally distributed data, differ-
ences between treatment groups were determined with
one-way analysis of variance (ANOVA) followed by
Tukey honestly significant difference (HSD) post hoc test.
In cases when Levene’s test for homogenicity gave statisti-
cal significance, Games–Howell post hoc test was applied.
Differences between treatment groups were considered
statistically significant if P < 0.05.
Results
Characterization of viral vector-mediated
expression in intact animals
Sensitivity and specificity of the in-house-built
CDNF-ELISA
Sensitivity of the CDNF-ELISA was determined to a mini-
mum concentration of 10 pg/mL of recombinant human
CDNF. In cross-reactivity tests, the assay recognized only
5% of mouse CDNF at the concentration 2 ng/mL.
Human recombinant MANF gave no signal in the assay
(highest tested concentration was 500 ng/mL). The ELISA
readings of hCDNF in all the control rat brain samples
(intact, AAV2-GFP- or vehicle-treated hemispheres) were
under the detection limit of the assay.
Time- and titer-dependent protein expression
following AAV-CDNF injection in vivo
The CDNF expression following intrastriatal AAV2-CDNF
injection was monitored with CDNF-ELISA and showed
both time and titer dependence (Fig. 2). A five-time
increase in the injected virus vector titer (from 2 9 108
to 1 9 109 vg) resulted in a statistically significant
increase from about 160 pg of CDNF/mg of total protein
to about 530 pg of CDNF/mg of total protein (P < 0.05,
one-way ANOVA [F2,9 = 16.792, P = 0.001] and Games–
Howell post hoc test) (Fig. 2A). In the striatum (Fig. 2B),
expression of hCDNF at about 180 pg/mg of total protein
could be detected already 1-week postinjection (AAV2-
CDNF 109 vg), followed by a quite robust increase in the
expression at 2-week postinjection (approximately 490 pg
of CDNF/mg of total protein). The expression remained
stable until the end of the study (12-week postinjection),
when the total amount of hCDNF in the dissected stria-
tum was 1.3  0.5 ng (approximately 780 pg of CDNF/
mg of total protein). After injecting AAV2-CDNF 109 vg
into the rat striatum, small amounts of hCDNF protein
could also be detected in the SN starting at 2-week
postinjection (Fig. 2D). In a small pilot study, the expres-
sion of GDNF 9 weeks after AAV2-GDNF injection was
ª 2013 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. 79
S. B€ack et al. AAV-CDNF in a Parkinson’s Disease Rat Model
shown to correlate with the expression of CDNF (com-
pare Fig. 2B and C).
Detection of protein expression with
immunohistochemistry
Twelve weeks after intrastriatal injection of AAV2-CDNF,
intensive CDNF signal was observed in the striatum
around the injection tract (Fig. 3A). Compared with
GDNF (Fig. 3F), the CDNF signal was to a larger extent
found inside the transduced cells. CDNF-immunoreactive
solitary cells were visible in the ipsilateral lateral globus
pallidus (GP) and SNpc (Fig. 3B and D). The anti-CDNF
antibody used recognizes also rat CDNF, and background
staining from endogenous CDNF was observed in the
contralateral GP and SN (Fig. 3C and E). Intrastriatal
injection of AAV2-GDNF resulted in widespread GDNF
immunoreactivity in the striatum, in the ipsilateral lateral
GP, and in the SNpc and SN pars reticulata (SNpr)
(Fig. 3F, G, and I). The majority of the CDNF-positive
cells (green) in the striatum around the injection tract
were NeuN positive (Fig. 3K), and the solitary CDNF-
immunoreactive cells found in the SNpc showed colocal-
ization with TH immunoreactivity (Fig. 3L).
Amphetamine-induced rotations
At 2- and 4-week postlesion (4- and 6- week after viral
vector injection), rats treated with AAV2-CDNF
(2 9 108 vg) showed a statistically significant reduction
in amphetamine-induced (2.5 mg/kg, i.p.) net ipsilateral
rotations as compared with the control group (results
from one-way ANOVA and Games–Howell post hoc test
in Fig. 4). At 6- and 10-week postlesion, AAV2-CDNF
1 9 109 vg significantly improved the rotation asymme-
try, while the lower titers (4 9 107 and 2 9 108 vg) had
no effect. Treatment with AAV2-GDNF (1 9 109 vg)
showed therapeutic effect throughout the experiment
(Fig. 4). Control rats showed a progressive increase in
ipsilateral rotations until 6-week postlesion. After that,
spontaneous recovery of the rotational behavior could be
detected in the control groups.
TH-immunohistochemistry
TH-reactive fiber density in the striatum
The amount of DAergic nerve terminals in the rat stria-
tum 10-week postlesion was estimated by measuring the
optical density of TH-reactive fibers. In control rats, there
was an approximately 78% loss of TH-reactive fiber den-
sity as compared with the intact side (Fig. 5A and B).
Treatment with AAV2-GDNF resulted in a statistically
significant protection of the TH-reactive fibers compared
with the control (58% loss of fiber density, P < 0.01, one-
way ANOVA [P = 0.004, F4,50 = 4.350] and Tukey HSD
post hoc test). In rats treated with AAV2-CDNF (109 vg),
an almost statistically significant increase in striatal TH-
reactive fiber density was observed (63% loss of density,
Tukey HSD post hoc test: P = 0.054).
TH-reactive cells in the SN
Ten weeks post lesion, TH-reactive cells in the SNpc were
counted bilaterally in six sections, covering approximately
(A)
(B) (C)
(D)
Figure 2. The level of hCDNF protein in the rat striatum (A, B) and
substantia nigra (SN) (D) following injection of AAV2-CDNF into the
striatum measured by our CDNF-ELISA assay (n = 4/measure point).
The protein expression was dependent on the injected AAV2 vector
titer, when measured 4 weeks after delivery of the hCDNF gene (A),
remained stable until the end of the experiment (12 weeks) (B), and
was comparable to that of GDNF following AAV-GDNF injection (C;
n = 3). CDNF protein could also be detected in the ipsilateral SN
following intrastriatal AAV2-CDNF injection (D). *P < 0.05 versus
AAV-CDNF 4 9 107 and 2 9 108 vg, one-way ANOVA and Games–
Howell post hoc test, n = 4/group (A, B, D), n = 3 (C).
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1400–1500 lm of the SNpc in the rostro–caudal direc-
tion. In the intact contralateral side, TH-reactive cell
counts varied between 6500 and 11,600, with an average
of 8650  150 cells. There was no difference in the
amount of TH-reactive cells in the intact side between the
different treatment groups.
Ten weeks post lesion, an approximately 62% decrease
in TH-reactive neurons could be detected in the lesioned
SNpc in control rats (Fig. 5C). When taking into account
all six nigral sections (ranging from approximately 4.5 to
6.0 mm posterior from bregma), none of the treatments
resulted in significant protection of the TH-reactive cells.
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
(I)
(J)
(K)
(L)
Figure 3. Expression of CDNF and GDNF proteins in the lesioned rat brain 12 weeks after injection of AAV2-CDNF or AAV2-GDNF into the
striatum. Expression of CDNF (A) and GDNF (F) was detected around the injection tract and the expression of CDNF colocalized with the neuronal
marker NeuN in the striatum (K). While CDNF protein was mainly found intracellularly, GDNF was evenly distributed in the tissue surrounding the
injection tract (insets in A, F). Solitary CDNF-immunoreactive cells were detected in the ipsilateral globus pallidus (GP) (B) and substantia nigra (SN)
(D). Some of the cells showing expression of hCDNF protein in the SNpc were TH positive (L). Following intrastriatal injection of AAV2-GDNF,
GDNF signal could be detected in the GP (G) and in both SN pars compacta and SN pars reticulata (I). Background staining of CDNF and GDNF is
shown in pictures C and E, and H and J, respectively. Scale bars: 200 lm (insets in A, F), 500 lm (B, C, D, E, G, H, I, J), and 10 lm (K, L).
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In rats treated with AAV2-GDNF, the cell loss was about
45% showing a trend toward protection of the TH-reac-
tive cells (P = 0.11, one-way ANOVA [P = 0.012,
F4,50 = 3.615] and Tukey HSD post hoc test).
When dividing the SNpc into a rostral, central, and
caudal parts (two sections/part), we could conclude that
the TH-reactive cell loss in the control group was con-
sistent throughout all three areas (approximately 59%,
64%, and 63%, respectively). In the rostral part (ranging
from about 4.5 to 5.0 mm posterior to bregma), no
treatment effect on the TH-reactive cell counts could be
seen (P = 0.065, F4,50 = 2.365, one-way ANOVA)
(Fig. 5D). In the central part of the SNpc (ranging from
about 5.0 to 5.5 mm posterior to bregma), treatment
with AAV2-CDNF 1 9 109 vg significantly protected the
TH-reactive neurons (37% cell loss, P < 0.05, one-way
ANOVA [P = 0.005, F4,50 = 4.193] and Tukey HSD post
hoc test). Following treatment with AAV2-GDNF, the
loss of TH-reactive cells was approximately 43%, but
the result did not reach statistical significance
(P = 0.139). In the caudal part (from about 5.5 to
6.0 mm posterior to bregma), treatment with AAV2-
GDNF showed a trend toward protection of the
TH-reactive neurons (41% cell loss as compared with
63% in the control group, P = 0.098, one-way ANOVA
[P = 0.026, F4,50 = 3.033] and Tukey HSD post hoc
test). In both the central and caudal parts, the rescue of
TH-reactive neurons following AAV2-CDNF treatment
showed titer dependence (Fig. 5D). While the same
degree of protective effect of AAV2-GDNF treatment
could be detected in all three subparts of the SNpc, the
effect of AAV2-CDNF 1 9 109 vg was mainly localized
to the central parts of the SNpc.
Sprouting of TH-positive fibers
In rats treated with AAV2-GDNF prior to 6-OHDA
lesioning, sprouting of TH-immunoreactive fibers in the
striatum (Fig. 6A), lateral GP (Fig. 6B), and SNpr
(Fig. 6C) could be seen. The areas that showed signs of
sprouting corresponded to areas with GDNF immunore-
activity (compare Fig. 6B and C with Fig. 3E and F).
Even if treatment with AAV2-CDNF showed a tendency
to protect the TH-reactive fibers in the striatum (see
above and Fig. 5C), no clear sprouting of TH-positive
fibers in either of the studied brain areas was observed.
When comparing 6-OHDA-lesioned rat brains treated
with AAV2-CDNF or with CDNF protein, there were dif-
ferences in the resulting pattern of TH-immunoreactive
fibers in the striatum (Fig. 6D). Although AAV2-CDNF
did not cause any clear sprouting in the striatum, treat-
ment with CDNF protein (both 3 lg/24 h and 4.5 lg/
24 h for 2 weeks) had an effect on striatal TH-positive
fibers similar to that seen after AAV2-GDNF treatment
(compare Fig. 6D and A, AAV2-GDNF) and treatment
with GDNF protein (3 lg/24 h; picture not shown).
Thus, the effect of intracellularly produced CDNF seems
to differ from the effect of extracellularly applied CDNF.
Figure 4. Amphetamine-induced (2.5 mg/kg, i.p.) rotational behavior was measured for 120 min at 2, 4, 6, 8, and 10 weeks following the
unilateral 6-OHDA lesion. Intrastriatal injection of AAV2-CDNF or AAV2-GDNF was able to attenuate the ipsilateral turning behavior. Intergroup
comparisons were assessed using one-way ANOVA (results showed in the upper right corner of each graph) and Games–Howell post hoc test.
*P < 0.05, **P < 0.01 versus control group, n = 9-18.
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Discussion
The main result of this study is that intrastriatal CDNF
gene therapy leads to expression of hCDNF in the brain
and functional recovery of neural circuits controlling
movements in 6-OHDA-lesioned rats. To the best of our
knowledge, this is the first study of intracranial gene
transfer of CDNF.
(A)
(B)
(C)
(D)
(E)
Figure 5. Tyrosine hydroxylase (TH) immunoreactivity in the rat striatum (A and B) and substantia nigra pars compacta (SNpc) (C, D, and E) 10
weeks post lesion (12 weeks after virus vector injection). Quantified results (A, C, and D) are given as percentage of the lesioned side as
compared with the intact side. The white line across the dorsal striatum shows the site of optical density measurements (B). Treatment with
AAV2-GDNF increased TH-reactive fiber density in the striatum as compared with the control group (A). Representative sections of TH staining in
the striatum are shown in (B). Stereological analysis of nearly the entire SNpc (from 4.5 to 6.0 mm posterior to bregma) showed that none of the
treatments were able to provide statistically significant protection of the TH-reactive neurons in the SNpc (C). AAV2-CDNF 1 9 109 vg was able
to protect the nigral TH-reactive cells in the central SNpc (D). Representative sections showing TH-reactive cells in the central SNpc are visualized
in (E). *P < 0.05, **P < 0.01 versus control, one-way ANOVA, and Tukey HSD post hoc test, n = 9-18. Scale bar: 500 lm.
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We have earlier shown that intrastriatal injection of
CDNF protein either as a single dose (Lindholm et al.
2007) or as a 2-week continuous infusion (Voutilainen
et al. 2011) is able to attenuate amphetamine-induced ipsi-
lateral rotation asymmetry in unilaterally 6-OHDA-
lesioned rats and protect TH-positive neurons in the SN
against 6-OHDA toxicity. Recently, CDNF was shown to
have neuroprotective and neurorestorative effects also in a
mouse MPTP model (Airavaara et al. 2012). In this study,
we were able to show that a single injection of AAV2-
CDNF leads to prolonged expression of hCDNF in the
brain. The protein expression was virus vector titer-depen-
dent and hCDNF was measured from striatum 1 week after
gene delivery and the expression remained stable up to at
least 12 weeks. In the SN, expression of hCDNF was
delayed and clearly seen only after 12 weeks. The amount
of expressed CDNF and GDNF proteins was similar to each
other at 8–9 weeks after virus vector injection. Thus, it is
obvious that the neuroprotection observed in this study is
due to expression of the neurotrophic factors in the brain.
The protection of TH-positive cells in the SN was rather
modest. This may be related to the pattern of protein
expression and the titers used. Thus, analyses of the striata
revealed a much more spatially restricted expression of
hCDNF as compared with that of GDNF. This may explain
why the protection of TH-reactive cells in the SNpc in
AAV2-CDNF-treated rats was seen mainly in the central
subdivision of the SN. In AAV2-GDNF-treated rats, pro-
tection of TH-reactive cells seemed to be more consistent
across all the analyzed nigral sections, although the effect
was statistically nonsignificant. TH-reactive cells from dif-
ferent anterior–posterior levels of the rat SN have been
reported to respond differently to both intrastriatal injec-
tions of 6-OHDA (Kirik et al. 1998) and to GDNF gene
therapy (single intrastriatal injection of recombinant aden-
oviral vector) (Choi-Lundberg et al. 1998). Whether this is
a consequence of the position of the striatal injection,
spreading, and distribution of the neurotrophic factor or
difference in the responsiveness of DAergic cells remains
unclear. In a previous study, where approximately nine
(A)
(B)
(C)
(D)
Figure 6. TH immunoreactivity in the striatum (STR) (A), globus pallidus (GP) (B), and substantia nigra pars reticulata (SNpr) (C) of the intact brain
and 6-OHDA-lesioned rats treated with AAV2-GFP, AAV2-GDNF, or AAV2-CDNF. Twelve weeks post lesion, the 6-OHDA injections had caused an
almost complete loss of TH-reactivity in the striatum, GP, and SNpr (AAV-GFP; A, B, and C). Injection of AAV2-GDNF 2 weeks before the 6-OHDA
injections caused an increase of TH-positive fibers in the striatum, GP, and SNpr (AAV2-GDNF; A, B, and C). Treatment with AAV2-CDNF did not
result in any clear sprouting, but caused an overall, partial protection of the TH-reactive fibers (A, B, and C) that was confirmed by the optical
density measurements in the striatum (Fig. 5C). Compared with AAV2-CDNF, infusion of CDNF protein resulted in a denser meshwork of
TH-reactive fibers close to the infusion tract (arrow) in the 6-OHDA-lesioned rats (D). Scale bars: 500 lm (A, B, C), 200 lm (D).
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times bigger AAV2-GDNF titer dose was divided into three
sites throughout the striatum intrastriatal AAV2-GDNF
was shown to provide significant protection of nigral
DAergic cells (Kirik et al. 2000). Therefore, it is likely that
the titers used in this study were too low to provide maxi-
mal protection of the midbrain DAergic neurons against
6-OHDA toxicity. Also, the transduction volume of AAV
serotype 2 is known to be low, and other serotypes provid-
ing better spread of the viral transgene and increased
expression (e.g., AAV serotype 5; Burger et al. 2004) would
probably also result in better protection of the nigrostriatal
pathway. On the other hand, AAV2-NRTN (CERE-120)
provided significant protection of nigral TH-reactive cells
even at viral vector doses as low as 1.6 9 108 vg (single-
site injection of 6-OHDA) (Gasmi et al. 2007a).
Delivery of AAV2-GDNF prior to 6-OHDA administra-
tion provided an increase in TH-immunoreactive fiber
density in the striatum, and sprouting of TH-immunore-
active fibers in the lateral GP and SNpr, as reported also
by others (Kirik et al. 2000; Kordower et al. 2000; Georgi-
evska et al. 2002a,b). We did not observe any sprouting
of TH-positive fibers in the striatum of AAV2-CDNF-
treated animals, even though the fiber density was partly
preserved. The apparent difference between the two neu-
rotrophic factors may be due to different patterns of
expression of the proteins (see above). The immunostain-
ing for GDNF was widespread while that of CDNF was
almost entirely intracellular. Indeed, we noticed earlier
that when CDNF was delivered as protein infusions into
6-OHDA-lesioned rat brain, it was able to induce signs of
sprouting in the striatum (Voutilainen et al. 2011).
Both AAV2-CDNF and AAV2-GDNF reduced amphet-
amine-induced turning in a similar manner with maximal
effect observed toward the end of the 12-week experi-
ment. It is interesting to note that the effect of the lower
titer of AAV2-CDNF (2 9 108 vg) was statistically signifi-
cant already at 2- and 4-week postlesion. At 6- and
10-week postlesion, only the higher titer (1 9 109 vg) sig-
nificantly improved the rotation asymmetry. The tempo-
ral differences in the statistical significances may reflect
the rather big variation in response to amphetamine
between individual animals. Starting from 6-week postle-
sion, a decrease in rotation asymmetry could also be seen
in the control groups, masking to a minor extent the
effect of the treatments. This kind of spontaneous recov-
ery has been observed before, and it may be due to an
increase of diffusion ability of DA in the striatum of
lesioned rats, or an increase in the amount of DA released
from remaining terminals (Doucet et al. 1986; Robinson
et al. 1994) and/or regrowth of DAergic fibers (Blanchard
et al. 1996). Even if the spontaneous recovery was taken
into account, the higher titer of CDNF (1 9 109 vg) had
a significant behavioral effect in the turning model.
Our CDNF-ELISA was sensitive and specific for
hCDNF, and confirmed the immunohistochemical find-
ings. Thus, although most of the hCDNF protein was
observed in the striatum, detectable amounts were also
found in the SN. In our previous work, following a sin-
gle intrastriatal injection, 125I-CDNF protein was trans-
ported to the SN and this transport could be blocked by
unlabeled CDNF protein (Voutilainen et al. 2011). How-
ever, it is also possible that the AAV2-CDNF vector itself
is transported from the striatum to SN (Paterna et al.
2004), inducing CDNF expression in the SN. In the
medial part of SNpc, CDNF staining was colocalized
with TH (a DA cell marker) which would support retro-
grade transport (of the protein or viral vector) along the
DAergic nigrostriatal axis. Alternatively, CDNF protein
in the SN could also be a result of anterograde transport
along direct GABAergic projections (Fallon and Loughlin
1995). The CDNF immunoreactivity in some solitary
cells in the ipsilateral lateral GP would also indicate
anterograde transport (of protein or viral vector) via the
indirect GABAergic pathway. GDNF is known to be
transported in both a retrograde (through DAergic pro-
jections) and anterograde (through both direct and indi-
rect GABAergic projections) fashion to the SN after
intrastriatal injection of either the protein (Tomac et al.
1995b; Ai et al. 2003) or viral vectors encoding GDNF
(Kirik et al. 2000; Kordower et al. 2000; Eslamboli et al.
2003; Johnston et al. 2009; Ciesielska et al. 2011). Also
in our hands, AAV-GDNF-treated rat brain showed clear
GDNF staining in the injected area (striatum), lateral
GP, SNpc, and SNpr.
The site of delivery is one major open question regard-
ing future gene therapy with neurotrophic factors in PD.
When the nigrostriatal DAergic projections are lost, in-
traputamenal delivery of therapeutic agents to target the
SN will probably require alternative routes of transporta-
tion. In this regard, GABAergic projections may play a
significant role (Kirik et al. 2000; Ciesielska et al. 2011).
It is also noteworthy that efficacy in a rodent model may
not guarantee efficacy in humans. In animal models of
PD, intrastriatal infusion of a recombinant AAV2-NRTN
vector (CERE-120) was effective in behavioral tests, and
NRTN immunoreactivity was traced to the striatum, GP,
endopeduncular nucleus, SNpc, and SNpr (Kordower
et al. 2006; Gasmi et al. 2007a,b; Herzog et al. 2007), sug-
gesting both retrograde and anterograde transport. How-
ever, when CERE-120 was delivered into the putamen of
PD patients, NRTN immunoreactivity was mainly
restricted to the injected area, with a very scanty NRTN
signal in the SN of postmortem brains (Bartus et al.
2011). The limited distribution of NRTN protein in the
human brain may explain the very modest improvement
in motor scores in the Phase 2 CERE-120 clinical trial
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(Marks et al. 2010). It is also consistent with the observa-
tion that in postmortem brains, there was very little
induction of TH following intraputamenal infusion of
CERE-120 (Bartus et al. 2011). In our study, only a
scanty CDNF immunoreactivity could be detected along
the anterograde indirect projections from the striatum to
SN, and therefore, CDNF evidently would need the direct
pathways. It is tempting to speculate that for an optimal
clinical effect, AAV2-CDNF should be administered close
to the SN, or to both the striatum and SN. Only when
the CDNF receptor is identified and its location is found,
further conclusions of the optimal administration site of
CDNF can be made.
In conclusion, AAV2-CDNF was able to induce func-
tional recovery of the rat midbrain neural circuitry to the
same extent as AAV2-GDNF. AAV2-CDNF did not pro-
duce significant sprouting of neither TH-reactive fibers in
the striatum nor increase in TH-positive cells in the
SNpc. The modest neuroprotection is most probably due
to rather low viral vector titers for both AAV2-CDNF and
AAV2-GDNF and in the case of AAV2-CDNF, restricted
and mainly intracellular expression of hCDNF protein.
However, our results indicate that AAV2-CDNF is an
alternative method for sustained delivery of CDNF pro-
tein in the brain. In the future, it would be important to
find out the level of protection using higher titers, multi-
ple injection sites, other vector serotypes, different pro-
moter, and/or different injection site. In addition, more
knowledge about the unique actions of CDNF on the
midbrain DAergic transmission or other neuronal path-
ways are needed to assess the full potential of AAV2-
CDNF as a therapy in PD.
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